Yih-Ing Hser1, Larissa J Mooney2, David Huang3, Yuhui Zhu4, Rachel L Tomko5, Erin McClure6, Chih-Ping Chou7, Kevin M Gray8. 1. Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, United States. Electronic address: yhser@ucla.edu. 2. Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, United States. Electronic address: lmooney@mednet.ucla.edu. 3. Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, United States. Electronic address: yhuang@ucla.edu. 4. Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, United States. Electronic address: yhzhu@ucla.edu. 5. Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, United States. Electronic address: tomko@musc.edu. 6. Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, United States. Electronic address: mccluree@musc.edu. 7. Institute of Preventive Medicine, University of Southern California, United States. Electronic address: cchou@usc.edu. 8. Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, United States. Electronic address: graykm@musc.edu.
Abstract
AIMS: This study examined the longitudinal association between reductions in cannabis use and changes in anxiety, depression, sleep quality, and quality of life. METHODS: Secondary analyses were conducted based on data from a cannabis use disorder medication trial in 302 adults (ages 18-50). Changes in symptoms of anxiety and depression, sleep quality, and quality of life were assessed in relation to changes in cannabis use during the 12-week trial of treatment. RESULTS: Based on the slope of individual cannabis use trajectory, the sample was classified into two groups (Cannabis Use Reduction, n=152 vs. Cannabis Use Increase, n=150) which was included as a binary covariate in subsequent modeling. Controlling for demographics (age, gender, race/ethnicity), treatment condition, and time-varying tobacco and alcohol use, separate latent growth curve models showed a significant association between the Cannabis Use Reduction group and improvement (i.e., lower values in slope) in anxiety (β=-0.09, SE=0.04; p<0.05), depression (β=-0.11, SE=0.04; p<0.01), and sleep quality (β=-0.07, SE=0.03; p<0.05) over the observation period, but not in quality of life. CONCLUSIONS: These results indicate a longitudinal relationship between reductions in cannabis use and improvements in anxiety, depression, and sleep quality. Clinicians treating patients with co-occurring cannabis use and problems with anxiety, depression, or sleep quality should attend to cannabis use reduction as a component of treatment.
RCT Entities:
AIMS: This study examined the longitudinal association between reductions in cannabis use and changes in anxiety, depression, sleep quality, and quality of life. METHODS: Secondary analyses were conducted based on data from a cannabis use disorder medication trial in 302 adults (ages 18-50). Changes in symptoms of anxiety and depression, sleep quality, and quality of life were assessed in relation to changes in cannabis use during the 12-week trial of treatment. RESULTS: Based on the slope of individual cannabis use trajectory, the sample was classified into two groups (Cannabis Use Reduction, n=152 vs. Cannabis Use Increase, n=150) which was included as a binary covariate in subsequent modeling. Controlling for demographics (age, gender, race/ethnicity), treatment condition, and time-varying tobacco and alcohol use, separate latent growth curve models showed a significant association between the Cannabis Use Reduction group and improvement (i.e., lower values in slope) in anxiety (β=-0.09, SE=0.04; p<0.05), depression (β=-0.11, SE=0.04; p<0.01), and sleep quality (β=-0.07, SE=0.03; p<0.05) over the observation period, but not in quality of life. CONCLUSIONS: These results indicate a longitudinal relationship between reductions in cannabis use and improvements in anxiety, depression, and sleep quality. Clinicians treating patients with co-occurring cannabis use and problems with anxiety, depression, or sleep quality should attend to cannabis use reduction as a component of treatment.
Authors: Sharon Levy; Lon Sherritt; Sion Kim Harris; Elizabeth C Gates; David W Holder; John W Kulig; John R Knight Journal: Alcohol Clin Exp Res Date: 2004-08 Impact factor: 3.455
Authors: Jillian E Halladay; Michael H Boyle; Catharine Munn; Susan M Jack; Katholiki Georgiades Journal: Can J Psychiatry Date: 2018-09-27 Impact factor: 4.356
Authors: Erin A McClure; Rachel L Tomko; Claudia A Salazar; Saima A Akbar; Lindsay M Squeglia; Evan Herrmann; Matthew J Carpenter; Erica N Peters Journal: Exp Clin Psychopharmacol Date: 2018-12-17 Impact factor: 3.157
Authors: Christina A Brezing; C Jean Choi; Martina Pavlicova; Daniel Brooks; Amy L Mahony; John J Mariani; Frances R Levin Journal: Am J Addict Date: 2018-02-19
Authors: Rachel L Tomko; Nathaniel L Baker; Caitlyn O Hood; Amanda K Gilmore; Erin A McClure; Lindsay M Squeglia; Aimee L McRae-Clark; Susan C Sonne; Kevin M Gray Journal: Psychopharmacology (Berl) Date: 2019-11-11 Impact factor: 4.530